Allergy Treatment Market Report by Worldwide Market Trends & Opportunities and Forecast to 2028

At 6.9% CAGR, the Global Allergy Treatment Market is anticipated to accumulate US$ 35,812.33 million by 2028, says The Insight Partners
According to The Insight Partners’ research, the global allergy treatment market was valued at US$ 21,160.92 million in 2020 and is projected to expand at a 6.9% CAGR between 2021 and 2028 to amass US$ 35,812.3 million by 2028. Increasing adoption of immunotherapy in allergy treatment and developments in food allergy treatments are the key factors aiding market augmentation.
Immunotherapy is offered in two types—allergy shots and sublingual immunotherapy (SLIT). Allergy shots are the extracts of allergens that are administered with increasing dosage; they are effective for allergies. The administration of a repetitive dosage of allergen makes patients less sensitive to that allergen, thus relieving allergic symptoms. Immunotherapy has shown positive and long-term benefits in allergic patients. Moreover, it is suitable for self-administration and medicine usage in homecare settings. Therefore, immunotherapy has emerged as a safe and effective alternative subcutaneous route for chronic and recurrent allergies. Various studies have shown that immunotherapy reduces allergic symptoms by 60–65% among patients who have completed their dosages of allergen. According to a study published in Annals of Allergy, Asthma and Immunology Journal in February 2016, ~70% of allergy patients do not need medications for their allergic reactions. The study also stated that immunotherapy is effective among children as well as the elderly population. Thus, the increasing adoption of immunotherapy in treating allergies is fueling the allergy treatment market growth.
Allergy is a common medical condition among a large share of the global population. It is one of the chronic health conditions that may result in severe consequences. Food allergies are ubiquitous in North America and Europe. According to the Center for Biologics Evaluation and Research of the Food and Drug Administration (FDA), ~1 million children in the US are allergic to peanuts, and one in five of these children is likely to surmount the respective allergy condition. Therefore, developing treatment options for allergies to such common foodstuff is essential. Pharmaceutical industry developments have enabled companies to offer treatment for peanut allergy reactions. Palforzia was developed by Aimmune Therapeutics, Inc., a Nestle Health Science Company. Such developments in the food allergy treatment options and their effectiveness are boosting the growth of the allergy treatment market.
Based on allergy type, the global allergy treatment market is divided into eye allergy, rhinitis, asthma, skin allergy, food allergies, and other allergies. Among these, the rhinitis segment held 39.06% of the market share in 2020. The segment was assessed at US$ 8,265.45 million in 2020 and is estimated to accumulate US$ 13,701.80 million by 2028, expanding at a 6.6% CAGR over 2021–2028.
As per the end route of administration, the market is arrayed into anti-allergy drugs and immunotherapy. Among these, the anti-allergy segment accounted for 89.88% of the market share in 2020. The segment was valued at US$ 19,018.62 million in 2020 and is anticipated to be worth US$ 31,603.17 million by 2028, growing at a 6.6% CAGR over the analysis timeframe. In May 2020, Stallergenes Greer May-20 Product News Stallergenes Greer, a biopharmaceutical company specializing in treatments for respiratory allergies, announced the expansion of the supply of subcutaneous products (SCIT), further broadening its offering to patients and the medical community through sustained investment in quality and operational excellence.
From the regional frame of reference, North America held a significant share in the global allergy treatment market in 2020. The regional market was valued at US$ 6,646.04 million in 2020 and is projected to be worth US$ 10,940.67 million by 2028. Further, Asia Pacific market is projected to expand at a stellar growth rate of 7.4% CAGR during the forecast period. In October 2017, Stallergenes Greer plc announced the acquisition of Medic Savoure Limited, a well-established allergy immunotherapy (AIT) leader in Canada. The acquisition strengthened Stallergenes Greer’s local presence and accelerated the company’s growth in Canada.
Leading players profiled in the global allergy treatment market report are Johnson and Johnson Services, Inc.; Sanofi; AbbVie Inc. (Allergan plc); Pfizer Inc.; LETIPharma; ALK-Abelló A/S; Allergy Therapeutics; Stallergenes Greer; GlaxoSmithKline plc; and Dermapharm Holding.